drugset / Trial / NCT00417677

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

NCT00417677

Phase 1/2 Terminated 124 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is being conducted to determine the Maximum Tolerated Dose (MTD) and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer

Timeline

Start
2007-03
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule
Subject Temsirolimus Small molecule

Indications